Project Grant R01DK138154

Award Date 7/1/24
Completion Date 5/31/29
Dollars Obligated $507K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This federal Project Grant award, valued at $516,648.00 and granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is focused on investigating the role of epigenetic memory in intestinal regeneration. The research aims to examine whether intestinal stem cells (ISCs) maintain a memory of inflammatory exposure, and how this affects their subsequent regenerative capacity....
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $125,000 to the Regents of the University of Michigan to conduct research on the metabolic regulation of pancreatic metaplasia and neoplasia. The key objectives are to: Mechanistically investigate how the loss of the ME1 enzyme contributes to acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) formation...
This federal Project Grant award of $577,694 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate the mechanisms underlying Type 3C diabetes (T3CD) associated with exocrine pancreas diseases like chronic pancreatitis and pancreatic ductal adenocarcinoma. The key objectives are to: 1) study gene regulation and electrophysiology in primary human islet cells from subjects with...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,558,188 to The Trustees of the University of Pennsylvania to investigate how changes in transcription factor and heterochromatin states impact liver development, homeostasis, and regeneration. The research aims to elucidate the molecular interactions between transcription...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to elucidate the innate and adaptive immune mechanisms governing neonatal immune responses and sterile inflammation. The $797,735 award will support a 5-year research project that utilizes a novel mouse model to investigate heightened early-life immune system reactivity that may underlie the propensity for inflammatory...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $162,512 to the Regents of the University of Minnesota to investigate the factors that support the expansion and function of long-lived effector CD8 T cells within the memory compartment. The key objectives are to determine what pro-inflammatory cytokines and other factors promote the formation and...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $133,249 to the University of Alabama at Birmingham (UAB) to investigate the role of the RNF20 histone modifier in pancreatic beta cell function and senescence. The primary objectives of this research project are to: 1) Evaluate how the loss of RNF20 in pancreatic beta cells...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $276,450 to The Salk Institute for Biological Studies to investigate the role of the PPARD/CIITA/MHCII axis in regulating regulatory T cell (Treg) function and its impact on tumor immunity. The key objectives are to: 1) define the molecular mechanisms by which MHCII expression in Tregs is regulated by the PPARD/CIITA...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $138,742 to The Johns Hopkins University to investigate immunotherapy-induced alterations to cellular communication networks in pancreatic ductal adenocarcinoma (PDAC). The key research objectives are to: 1) develop statistical methods to identify cellular interactions that differ between immunotherapy treatment groups in single-cell RNA sequencing data from PDAC clinical trials, and...
This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...

DEFINING THE MOLECULAR DETERMINANTS OF INFLAMMATORY MEMORY IN THE PANCREAS - PROJECT SUMMARY / ABSTRACT BIOLOGICAL SYSTEMS OPERATE WITHIN FLUCTUATING ENVIRONMENTS, AND, THEREFORE, ARE INHERENTLY TASKED WITH ACCURATELY RESPONDING IN REAL-TIME TO A MYRIAD OF SIGNALS. RECENT EVIDENCE SUGGESTS THAT A MEMORY OF INFLAMMATION CAN BE ENCODED AND RETAINED IN THE EPIGENOME OF CELLS EVEN FOLLOWING RESOLUTION OF THE INITIAL STIMULUS. THE PRESENCE OF `INFLAMMATORY MEMORY' SUGGESTS THAT PRESERVATION OF TISSUE HOMEOSTASIS ALSO INCORPORATES AN EVOLUTIONARY ADAPTATION IN WHICH FUTURE RESPONSES ARE EDUCATED BY PAST EXPERIENCES. INFLAMMATION IS ESSENTIAL TO THE DISRUPTION OF TISSUE HOMEOSTASIS, AND, IN THE PANCREAS, CAN DESTABILIZE THE IDENTITY OF TERMINALLY DIFFERENTIATED ACINAR CELLS. RECENTLY, WE HAVE EMPLOYED LINEAGE-TRACED MOUSE MODELS TO DELINEATE THE CHROMATIN DYNAMICS THAT ACCOMPANY THE CYCLE OF METAPLASIA AND REGENERATION FOLLOWING PANCREATITIS, AND UNVEILED THE PRESENCE OF AN EPIGENETIC MEMORY OF INFLAMMATION IN THE PANCREATIC ACINAR CELL COMPARTMENT. WE HAVE OBSERVED THAT DESPITE HISTOLOGIC RESOLUTION OF PANCREATITIS, ACINAR CELLS FAIL TO RETURN TO THEIR MOLECULAR BASELINE AFTER SEVERAL MONTHS, REPRESENTING AN INCOMPLETE CELL FATE DECISION - ONE WHEREIN THERE IS PERSISTENT MAPK SIGNALING, AP-1 ACTIVATION, AND IL-33 IN THE PANCREAS MICROENVIRONMENT. IN VIVO, THIS EPIGENETIC MEMORY CONTROLS LINEAGE PLASTICITY, WITH DIMINISHED METAPLASIA IN RESPONSE TO A SECOND INFLAMMATORY INSULT BUT INCREASED TUMORIGENESIS WITH AN ONCOGENIC KRAS MUTATION. WE HAVE DEMONSTRATED THAT BOTH PERSISTENT CHROMATIN AND TRANSCRIPTIONAL CHANGES CONSTITUTING MEMORY CAN BE SPECIFICALLY RECALLED IN THE RESPONSE TO ONCOGENIC STRESS. TOGETHER, OUR FINDINGS HAVE DEFINED THE DYNAMICS AND RECALL OF AN EPIGENETIC MEMORY OF INFLAMMATION THAT IMPACTS CELL FATE DECISIONS. IN THIS PROPOSAL, WE FOCUS ON BUILDING AN UNDERSTANDING OF THE MOLECULAR UNDERPINNINGS OF MEMORY OF INFLAMMATION. SPECIFICALLY, WE WILL LEVERAGE OUR LINEAGE-TRACED MOUSE MODELS OF PANCREATIC INFLAMMATION TO ESTABLISH AN UNDERSTANDING OF AP-1 BINDING TO CHROMATIN AND ITS INTERACTION PARTNERS (AIM 1). WE WILL ALSO EMPLOY SPECIFIC GENETIC AND PHARMACOLOGIC PERTURBATIONS TO AP-1 FACTORS AND MAPK SIGNALING IN VIVO TO ARTICULATE WHETHER EPIGENETIC MEMORY IS REVERSIBLE (I.E. INDUCING EPIGENETIC `AMNESIA') (AIM 2). THIRD, WE WILL EXAMINE THE ROLE OF IL-33 AS A CELL-EXTRINSIC FACTOR DRIVING THE MEMORY PHENOTYPE (AIM 3). TOGETHER OUR STUDIES WILL DEFINE THE MOLECULAR MECHANISMS THAT GOVERN EPIGENETIC MEMORY OF INFLAMMATION IN THE PANCREAS. IN SO DOING, WE EXPECT TO UNCOVER THE KEY CELL TYPES, TRANSCRIPTION FACTORS, AND SIGNALING INTERMEDIATES THAT LEAD TO PERSISTENT MOLECULAR ALTERATIONS FOLLOWING TRANSIENT INJURY. IN TURN, THIS WORK WILL SHED NEW LIGHT IN TO HOW MEMORY CAN BE TARGETED TO ABROGATE THE DIMINISHED THRESHOLD FOR TUMORIGENESIS. BY ANALYZING THE RATIONAL MEANS FOR INDUCING EPIGENETIC `AMNESIA', WE WILL EXPLOIT THE THERAPEUTIC OPPORTUNITY THAT THE DURABILITY OF EPIGENETIC MEMORY OFFERS TO ADDRESS THE LASTING IMPLICATIONS OF AN INFLAMMATORY INSULT.

Posted 6/27/24, 12:00 AM